**Core tip:** Non-*albicans Candida* prosthetic joint infections (PJIs) are rare, and no clear guidelines exist regarding the treatment of these infections. The purpose of this study was to clarify, by reviewing current published cases, the treatment options of non-*albicans Candida* PJIs and, possibly, to improve the medical and surgical care of such cases. A literature review of all existing non-*albicans Candida* PJIs cases through April 2018 was conducted. The combination of two stage revision arthroplasty and administration of prolonged antifungal therapy after initial resection arthroplasty is suggested on the basis of limited data.

INTRODUCTION
============

Prosthetic joint infection (PJI) is a severe complication of joint surgery, involving the joint prostheses and contiguous tissue, representing a main cause of total arthroplasty failure\[[@B1]\]. A plethora of microorganisms have been held responsible for these infections, such as Gram-positive and negative bacteria, while fungal microorganisms are considered rare causes. Fungal PJIs occur in about 1-2% of all cases, while the most common spread type seems to be hematogenous\[[@B2]\].

Optimal treatment is considered the two stage revision surgery in combination with an antifungal agent. However, no clear guidelines have yet been developed regarding the agent and treatment duration. Hence, a broad range of antifungal and surgical treatments have been reported so far\[[@B3],[@B4]\].

*Candida* spp represent the most common fungal pathogens for PJIs, with *Candida albicans* being the most prevalent species. However, over the last years, the incidence of non-*albicans Candida* PJIs has increased\[[@B4],[@B5]\]. The purpose of this study was to clarify, by reviewing current published cases, the treatment options of non-*albicans Candida* PJIs in order to potentially improve the medical and surgical care of such cases.

MATERIALS AND METHODS
=====================

A search of PubMed and MEDLINE databases was performed to identify all existing articles reporting the management of non-*albicans Candida* PJIs cases through April 2018. Isolated and combined terms of "fungal prosthetic joint infection", "fungal arthroplasty infection", "fungal hip arthroplasty infection", "fungal knee arthroplasty infection", "fungal shoulder arthroplasty infection", as well as terms including each non-*albicans Candida* species (*e.g*., "*candida glabrata* joint infection", "*candida parapsilosis* joint infection, *etc*) were used. The citations in each article were reviewed to locate additional references that were not retrieved during the initial search.

The present review is limited to papers published in English, peer-reviewed journals. Furthermore, cases without information about management and treatment were excluded. The data extracted from these studies included age, gender, affected joint, responsible non-*albicans Candida* species, duration and type of antifungal treatment, type of surgical treatment, time between initial arthroplasty and symptom onset, time between symptom onset and definite diagnosis (culture), outcome of the infection and follow-up of each case. Charlson Comorbidity score was calculated, when possible, by two independent investigators based on the information provided from each report.

Data were recorded and analyzed using Microsoft Excel 2010 (Microsoft Corporation, Redmond, Washington). Two-sided Fisher's exact tests were used to compare success rates between groups. Statistical analyses were carried out at the 5% level of significance.

RESULTS
=======

Table [1](#T1){ref-type="table"} highlights the findings from the electronic search, covering a 39 year period ending in 2018. A total of 83 non-*albicans Candida* PJIs were identified\[[@B4],[@B6]-[@B47]\]. A total of 46 cases (55.4%) were female patients, thirty-six male (43.4%), while in one case the gender was not clarified. The mean age of the study population was 66.3 years \[standard deviation (SD) = 10.2\]. The affected joint was the knee in 52 cases (62.6%), the hip in 29 (35%) and the shoulder in two (2.4%). Two of the knee prosthetic joint cases were bilateral. The mean Charlson comorbidity index of patients was 4.4 (SD = 1.5).

###### 

Non-*albicans Candida* prosthetic joint infection cases

  **Ref**.                       **Year**   **Fungus**           **Gender**                               **Age**                              **Joint**        **Charlson comorbidity index**   **Antifungal treatment**                                   **Surgical treatment**                   **Treatment duration**                           **Outcome**                                    **Follow-up in** **mo**   **Time from implantation to symptoms onset in mo**   **Time from symptoms onset to definite diagnosis by culture, in mo**
  ------------------------------ ---------- -------------------- ---------------------------------------- ------------------------------------ ---------------- -------------------------------- ---------------------------------------------------------- ---------------------------------------- ------------------------------------------------ ---------------------------------------------- ------------------------- ---------------------------------------------------- ----------------------------------------------------------------------
  Koutserimpas et al\[[@B6]\]    2018       *C. glabrata*        Female                                   68                                   Knee             4                                Anidulafungin / Voriconazole                               TSRA                                     28 wk                                            Successful                                     \-                        180                                                  0.5
  Geng et al\[[@B7]\]            2016       *C. glabrata*        Male                                     78                                   Hip              4                                Fluconazole / Amphotericin B / Caspofungin                 Spacer implantation (failure)/RA         26 wk                                            Successful                                                               11                                                   34.8
  Klatte et al\[[@B8]\]          2014       *C. glabrata*        Female                                   81                                   Hip              4                                Flucytosine / Amphotericin. B / Fluconazole                OSRA                                     \-                                               Successful                                                               8                                                    \-
  Zhu et al\[[@B9]\]             2014       *C. glabrata*        Male                                     44                                   Hip              \-                               Amphotericin B / Voriconazole                              No                                       6 wk                                             Successful                                     3                         \-                                                   5
  Anagnostakos et al\[[@B10]\]   2012       *C. glabrata*        Female                                   51                                   Hip              6                                Fluconazole                                                TSRA                                     6 wk                                             Successful                                     70                        \-                                                   \-
  Anagnostakos et al\[[@B10]\]   2012       *C. glabrata*        Male                                     78                                   Hip              6                                Fluconazole                                                TSRA                                     6 wk                                             Successful                                     15                        \-                                                   \-
  Bartalesi et al\[[@B11]\]      2012       *C. glabrata*        Female                                   60                                   Hip              \-                               Voriconazole / Caspofungin + Amphotericin B                TSRA                                     6 wk                                             Successful                                     48                        \-                                                   \-
  Hall et al\[[@B12]\]           2012       *C. glabrata*        Female                                   60                                   Hip              4                                Caspofungin                                                RA                                       6 wk                                             \-                                             \-                        \< 0.5                                               0.2
  Dumaine et al\[[@B13]\]        2008       *C. glabrata*        \-                                       72                                   Knee             5                                Caspofungin + Flucytosine / Fluconazole + Flucytosine      Arthrodesis                              16 wk                                            Successful                                     15                        \-                                                   \-
  Lejko-Zupanc et al\[[@B14]\]   2005       *C. glabrata*        Male                                     74                                   Hip              5                                Amphotericin B + Fluconazole / Caspofungin                 RA                                       → 3 wk                                           Successful                                     36                        72                                                   \-
  Fabry et al\[[@B15]\]          2005       *C. glabrata*        Female                                   74                                   Knee             6                                Voriconazole                                               2x Debridement                           32 wk                                            Death from unrelated causes while on therapy   24                        72                                                   \-
  Gaston et al\[[@B16]\]         2004       *C. glabrata*        Female                                   42                                   Knee             4                                Voriconazole / Amphotericin B                              Amputation (above knee)                  8 wk                                             Successful                                     6                         264                                                  \-
  Açikgöz et al\[[@B17]\]        2002       *C. glabrata*        Female                                   70                                   Knee             \-                               Fluconazole                                                Arthrodesis                              \-                                               Successful                                     7.5                       9                                                    6
  Ramamohan et al\[[@B18]\]      2001       *C. glabrata*        Female                                   65                                   Hip              \-                               Amphotericin B + Flucytosine                               TSRA                                     7 wk                                             Successful                                     24                        48                                                   \-
  Selmon et al\[[@B19]\]         1998       *C. glabrata*        Female                                   75                                   Knee             5                                Amphotericin B/Itraconazole + Fluconazole                  OSRA                                     \> 8 wk                                          Successful                                     48                        84                                                   \-
  Nayeri et al\[[@B20]\]         1997       *C. glabrata*        Female                                   62                                   Hip              4                                Amphotericin B+ Flucytosine / Itraconazole + Flucytosine   OSRA                                     11 wk                                            Successful                                     22                        60                                                   \-
  Darouiche et al\[[@B21]\]      1989       *C. glabrata*        Female                                   69                                   Hip              \-                               Amphotericin B                                             RA                                       1 wk                                             Successful                                     \-                        27                                                   0.5
  Goodman et al\[[@B22]\]        1983       *C. glabrata*        Female                                   69                                   Hip              3                                \-                                                         RA                                       \-                                               Successful                                     12                        27                                                   \-
  Geng et al\[[@B7]\]            2016       *C. papapsilosis*    Male                                     67                                   Knee             3                                Fluconazole                                                TSRA                                     10 wk                                            Successful                                     48                        3                                                    \-
  Wang et al\[[@B23]\]           2015       *C. parapsilosis*    Female                                   67                                   Knee             4                                Fluconazole                                                TSRA                                     10 wk                                            Successful                                     27                        \-                                                   \-
  Wang et al\[[@B23]\]           2015       *C. parapsilosis*    Male                                     74                                   Knee             5                                Fluconazole                                                TSRA                                     8 wk                                             Successful                                     30                        \-                                                   \-
  Wang et al\[[@B23]\]           2015       *C. pasapsilosis*    Female                                   71                                   Knee             4                                Fluconazole                                                TSRA                                     6 wk                                             Successful                                     62                        \-                                                   \-
  Klatte et al\[[@B8]\]          2014       *C. parapsilosis*    Male                                     69                                   Knee             8                                Flucytosine+ Amphotericin. B                               OSRAx3 (Failure the first 2 times)       \-                                               Successful                                     19                        1                                                    \-
  Klatte et al\[[@B8]\]          2014       *C. parapsilosis*    Female                                   82                                   Knee             4                                Flucytosine+ Amphotericin. B                               OSRA                                     \-                                               Successful                                                               2                                                    \-
  Klatte et al\[[@B8]\]          2014       *C. parapsilosis*    Male                                     46                                   Knee             1                                Flucytosine+ Amphotericin. B                               OSRA                                     \-                                               Successful                                                               6                                                    \-
  Ueng et al\[[@B24]\]           2013       *C. parapsilosis*    Male                                     62                                   Knee             4                                Fluconazole                                                TSRA                                     \-                                               Successful                                     ≥ 24                      4.5                                                  1.5
  Ueng et al\[[@B24]\]           2013       *C. parapsilosis*    Male                                     77                                   Knee             \-                               Fluconazole                                                TSRA                                     \-                                               Successful                                     ≥ 24                      4                                                    3
  Ueng et al\[[@B24]\]           2013       *C. parapsilosis*    Male                                     66                                   Hip              \-                               Fluconazole                                                TSRA                                     \-                                               Successful                                     ≥ 24                      2                                                    1
  Ueng et al\[[@B24]\]           2013       *C. parapsilosis*    Male                                     76                                   Knee             8                                Fluconazole                                                TSRA                                     \-                                               Successful                                     ≥ 24                      33                                                   2
  Ueng et al\[[@B24]\]           2013       *C. parapsilosis*    Male                                     36                                   Knee             \-                               Fluconazole                                                TSRA                                     \-                                               Successful                                     ≥ 24                      74                                                   2
  Ueng et al\[[@B24]\]           2013       *C. parapsilosis*    Male                                     66                                   Hip              4                                Fluconazole                                                RA                                       \-                                               \-                                             \-                        2                                                    2
  Kuiper et al\[[@B25]\]         2013       *C. parapsilosis*    Male                                     58                                   Hip              \-                               None                                                       RA/refused further treatment             \-                                               Refused further treatment                      8                         \-                                                   \-
  Chiu et al\[[@B26]\]           2013       *C. parapsilosis*    Male                                     71                                   Hip              5                                Fluconazole                                                RA                                       40 wk                                            Successful                                     24                        48                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. parapsilosis*    Female                                   71                                   Knee             \-                               Amphotericin B / Fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     46                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. parapsilosis*    Female                                   76                                   Knee             \-                               Amphotericin B / Fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     56                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. parapsilosis*    Female                                   76                                   Knee             \-                               Amphotericin B / Fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     67                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. parapsilosis*    Female                                   72                                   Knee             \-                               Fluconazole,                                               TSRA                                     ≥ 6 wk                                           Successful                                     73                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. parapsilosis*    Female[1](#T1FN1){ref-type="table-fn"}   61[1](#T1FN1){ref-type="table-fn"}   Bilateral Knee   \-                               Amphotericin B / Fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     65                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. parapsilosis*    Female[1](#T1FN1){ref-type="table-fn"}   61[1](#T1FN1){ref-type="table-fn"}   Bilateral Knee   \-                               Amphotericin B / Fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     46                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. parapsilosis*    Female                                   67                                   Knee             \-                               Amphotericin B / Fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     65                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. parapsilosis*    Female                                   68                                   Knee             \-                               Fluconazole,                                               TSRA                                     ≥ 6 wk                                           Successful                                     69                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. parapsilosis*    Female                                   68                                   Knee             \-                               Fluconazole,                                               TSRA                                     ≥ 6 wk                                           Successful                                     42                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. parapsilosis*    Female                                   67                                   Knee             \-                               Amphotericin B / Fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     49                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. parapsilosis*    Female                                   60                                   Knee             \-                               Amphotericin B / Fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     41                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. parapsilosis*    Female                                   73                                   Knee             \-                               Amphotericin B / Fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     52                        \-                                                   \-
  Anagnostakos et al\[[@B10]\]   2012       *C. parapsilosis*    Male                                     67                                   Knee             \-                               Fluconazole                                                RA                                       6 wk                                             \-                                             \-                        \-                                                   \-
  Dutronc et al\[[@B27]\]        2010       *C. parapsilosis*    Male                                     66                                   Hip              5                                Fluconazole                                                TSRA                                     24 wk                                            Successful                                     \-                        0                                                    \-
  Dutronc et al\[[@B27]\]        2010       *C. parapsilosis*    Female                                   77                                   Hip              4                                Ampotericin B + fluorocytosine / Fluconazole               RA                                       38 wk                                            Successful                                     \-                        5                                                    \-
  Antony et al\[[@B28]\]         2008       *C. parapsilosis*    Female                                   67                                   Shoulder         3                                Voriconazole / Fluconazole                                 TSRA                                     \-                                               Successful                                     6                         \-                                                   \-
  Antony et al\[[@B28]\]         2008       *C. parapsilosis*    Female                                   67                                   Hip              3                                Fluconazole                                                TSRA                                     \-                                               Successful                                     \-                        \-                                                   \-
  Yang et al\[[@B29]\]           2001       *C. parapsilosis*    Female                                   68                                   Knee             3                                Fluconazole                                                TSRA                                     10 wk                                            Successful                                     48                        0                                                    16
  Bruce et al\[[@B30]\]          2001       *C. parapsilosis*    Female                                   51                                   Hip              \-                               Fluconazole                                                TSRA                                     \-                                               Successful                                     84                        36                                                   36
  Brooks\[[@B31]\]               1998       *C. parapsilosis*    Male                                     64                                   Knee             5                                Amphotericin B/Fluconazole                                 Debridement                              28 wk                                            Successful                                     24                        15                                                   4
  Wada et al\[[@B32]\]           1998       *C. parapsilosis*    Male                                     77                                   Knee             4                                Fluconazole                                                Debridement                              28 wk                                            Successful                                     36                        0.5                                                  0.5
  Cushing et al\[[@B33]\]        1997       *C. parapsilosis*    Female                                   73                                   Knee             \-                               Fluconazole                                                No                                       \> 24 wk                                         Successful                                     12                        1                                                    \-
  Fukasawa et al\[[@B34]\]       1997       *C. parapsilosis*    Female                                   80                                   Knee             \-                               Fluconazole                                                Debridement                              53 wk                                            Successful                                     24                                                                             2
  White et al\[[@B35]\]          1995       *C. parapsilosis*    Female                                   64                                   Knee             \-                               Fluconazole/Ampotericin B / Itraconazole                   RA                                       20 wk                                            Successful                                     \-                        0                                                    9
  Tunkel et al\[[@B36]\]         1993       *C. parapsilosis*    Male                                     37                                   Knee             6                                Amphotericin B / Ketoconazole / Fluconazole                TSRA (Failure)/Amputation (Successful)   \-                                               Successful                                     7                         4                                                    0
  Paul et al\[[@B37]\]           1992       *C. pasapsilosis*    Male                                     63                                   Knee             \-                               Amphotericin + fluorocytosine / ketoconazole               Arthrodesis                              9 wk                                             Successful                                     24                        3                                                    4
  Lim et al\[[@B38]\]            1986       *C. parapsilosis*    Male                                     35                                   Knee             \-                               Fluorocytosine                                             Arthrodesis                              \-                                               \-                                             \-                        0                                                    6
  Younkin et al\[[@B39]\]        1984       *C. parapsilosis*    Female                                   75                                   Hip              \-                               Fluorocytosine+ Amphotericin B                             TSRA                                     6 wk                                             Successful                                     24                        0                                                    60
  Lichtman\[[@B40]\]             1983       *C. parapsilosis*    Male                                     59                                   Shoulder         \-                               Amphotericin B / ketoconazole                              RA                                       Indefinite (\> 58 d)                             \--                                            \-                        20                                                   9
  MacGregor et al\[[@B41]\]      1979       *C. parapsilosis*    Male                                     64                                   Knee             \-                               Amphotericin B + Fluorocytosine                            Non-surgical (failure)/ then RA          21 wk                                            Successful                                     12                        27                                                   5
  Sebastian et al\[[@B42]\]      2017       *C. tropicalis*      Male                                     53                                   Hip              3                                Fluconazole                                                TSRA                                     28 wk                                            Successful                                     NR                        24                                                   0
  Reddy et al\[[@B43]\]          2013       *C. tropicalis*      Female                                   62                                   Knee             3                                Fluconazole                                                TSRA                                     30 wk                                            Successful                                     24                        22.5                                                 1.5
  Ueng et al\[[@B24]\]           2013       *C. tropicalis*      Male                                     67                                   Hip              \-                               Fluconazole                                                RA                                       \-                                               \-                                             \-                        15                                                   1
  Lidder et al\[[@B44]\]         2013       *C. tropicalis*      Female                                   76                                   Hip              \-                               Amphotericin B                                             RA                                       24 wk                                            Successful                                     24                        36                                                   15
  Azam et al\[[@B45]\]           2008       *C. tropicalis*      Male                                     73                                   Hip              6                                Caspofungin / Fluconazole                                  TSRA                                     ≥ 9 wk, (Caspofungin 1 wk, fluconazole ≥ 8 wk)   Successful                                     12                        108                                                  \-
  Wyman et al\[[@B46]\]          2002       *C. tropicalis*      Male                                     62                                   Knee                                              Fluconazole / Amphotericin B                               TSRA                                     18 wk                                            Successful                                     36                        0.25                                                 6
  Darouiche et al\[[@B21]\]      1989       *C. tropicalis*      Male                                     72                                   Hip              4                                Amphotericin B / ketoconazole                              Debridement (failure)/ RA                12 wk                                            Successful                                     36                        0.5                                                  1
  Lambertus et al\[[@B47]\]      1988       *C. tropicalis*      Male                                     61                                   Hip              3                                Amphotericin B                                             RA                                       \-                                               Successful                                     24                        6                                                    6
  Lambertus et al\[[@B47]\]      1988       *C. tropicalis*      Male                                     65                                   Hip              \-                               Amphotericin B / ketoconazole                              RA/ arthrodesis                          \>24 wk                                          Successful                                     14                        4                                                    4
  73.Goodman et al\[[@B30]\]     1983       *C. tropicalis*      Female                                   59                                   Knee             \-                               Amphotericin B                                             TSRA (failure)/ RA                       6 wk                                             Successful                                     12                        3                                                    6
  Hwang et al\[[@B4]\]           2012       *C. pelliculosa*     Female                                   67                                   Knee             \-                               Fluconazole                                                TSRA                                     ≥ 6 wk                                           Successful                                     56                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C .pelliculosa*     Female                                   64                                   Knee             \-                               Amphotericin B / fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     35                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. pelliculosa*     Male                                     75                                   Knee             \-                               Amphotericin B / fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     34                        \-                                                   \-
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Klatte et al\[[@B8]\]          2014       *C. lusitaniae*      Male                                     74                                   Knee             6                                Voriconazole                                               OSRA                                     \-                                               Successful                                                               12                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. lusitaniae*      Female                                   66                                   Knee             \-                               Amphotericin B / fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     43                        \-                                                   \-
  Hwang et al\[[@B4]\]           2012       *C. famata*          Female                                   83                                   Knee             \-                               Amphotericin B / fluconazole                               TSRA                                     ≥ 6 wk                                           Successful                                     33                        \-                                                   \-
  Anagnostakos et al\[[@B10]\]   2012       *C. lipolytica*      Male                                     77                                   Hip              7                                Fluconazole                                                TSRA                                     6 wk                                             Successful                                     22                        \-                                                   \-
  Wang et al\[[@B23]\]           2015       *C. utilis*          Female                                   56                                   Knee             2                                Fluconazole                                                TSRA                                     6 wk                                             Successful                                     24                        \-                                                   5
  Dutronc et al\[[@B27]\]        2010       *C. guillermondii*   Male                                     76                                   Knee             4                                Amphotericin B+ fluorocytosine / Fluconazole               None                                     14 wk (2 wk AMB+5FC, then 3 mo FZ)               Failure                                        \-                        0                                                    \-
  Geng et al\[[@B7]\]            2016       *C. freyschussii*    Female                                   58                                   Knee             2                                Fluconazole / Caspofungin                                  TSRA                                     10 wk                                            Successful                                     55                        \<0.25                                               

Patient demographics, antifungal treatment, its duration, as well as infection outcome and follow-up period are presented.

Bilateral PJI in the same patient; -: Not reported or unclear. TSRA: Two stage revision arthroplasty; OSRA: One stage revision arthroplasty; RA: Resection arthroplasty.

The mean time from initial arthroplasty implantation surgery to symptom onset was 27.2 mo (SD = 43), while the mean time from symptom onset to culture-confirmed diagnosis was 7.5 mo (SD = 12.5). Regarding the causative non-*albicans Candida* species, the most frequently isolated one was *C. parapsilosis*, found in 45 cases (54.2%), followed by *C. glabrata* in 18 (21.7%), *C. tropicalis* in ten (12%), *C pelliculosa* in three (3.6%) and *C. lusitanae* in two (2.4%), while *C. famata*, *C. lipolytica*, *C. utilis*, *C. guilliermondii* and *C. freyschussii* had caused one case each (1.2%) (Figure [1](#F1){ref-type="fig"}).

![Prosthetic joint infection causative non-*albicans Candida* species.](WJCC-7-1430-g001){#F1}

Regarding surgical treatment, in the majority of the described cases (44 cases; 53%) a two stage revision arthroplasty (TSRA) was performed, followed by resection arthroplasty (RA) (18 cases; 22%), one stage revision arthroplasty (OSRA) (eight cases; 9.6%), arthrodesis (five cases; 6%), debridement (three cases; 3.6%) and amputation (two cases; 2.4%). In three cases (3.6%), there was no surgical treatment (Figure [2](#F2){ref-type="fig"}). TSRA exhibited a success rate of 96%, RA a rate of ≥ 61% \[in 7 cases information about the infection outcome was not provided (studies 8, 31, 32, 46, 60, 62, 66 in Table [1](#T1){ref-type="table"})\], OSRA a rate of 73%, debridement a rate of 75%, amputation a rate of 100%, while no surgical treatment has shown a success rate of 60%. TSRA when compared to OSRA had a higher success rate (96% *vs* 73%; *P*-value = 0.023).

![Surgical treatment for non-*albicans Candida* prosthetic joint infection. TSRA: Two stage revision arthroplasty; OSRA: One stage revision arthroplasty; RA: Resection arthroplasty.](WJCC-7-1430-g002){#F2}

Regarding the preferred antifungal agent, 38 cases (45.8%) were treated with a single drug, 29 (34.9%) with two, 12 (14.5%) with more than two, while one case did not receive antifungal treatment \[(1.2%); case 17 in Table [1](#T1){ref-type="table"}; the antifungal agent was not reported in case 32\].

Fluconazole was used in most cases \[59; (71%), in 31 of them (52.5%) as monotherapy\], followed by amphotericin B \[41; (49.4%), in 4 (9.8%) as monotherapy\], flucytosine \[13; (15.7%), in 1 (7.7%) as monotherapy\], caspofungin \[7; (8.4%), in 1 (14.3%) as monotherapy\], voriconazole \[7; (8.4%), in 2 (28.6%) as monotherapy\], ketoconazole \[5; (6%), none as monotherapy\], itraconazole \[3; (3.6%), none as monotherapy\] and anidulafungin \[l; (1.2%), not as monotherapy\]. The final outcome was successful in 74 cases (89.2%).

The majority of patients with *C. parapsilosis* PJIs were treated with fluconazole \[30 cases; (66.7%), in 22 (73.3%) as monotherapy\], followed by amphotericin B \[19; (42.2%), none as monotherapy\], flucytosine \[8; (17.8%), in 1 (12.5%) as monotherapy\], ketoconazole \[3; (6.7%), none as monotherapy\], while voriconazole and itraconazole were used in 1 case each (none as monotherapy). Outcome was successful in 40 cases (88.9%).

The majority of cases with *C. glabrata* PJIs were treated with amphotericin B \[8; (44.4%), in 1 (12.5%) as monotherapy\], followed by fluconazole \[7; (38.9%), in 3 (42.9%) as monotherapy\]. Caspofungin and voriconazole were used in 5 cases (27.8%) each, in 1 (20%) case each as monotherapy. Furthermore, three (16.7%) patients received flucytosine (none as monotherapy), two (11.1%) itraconazole (none as monotherapy) and one (5.6%) anidulafungin (not as monotherapy). Outcome was successful in 17 cases (94.4%), while one patient (case number 11 in Table [1](#T1){ref-type="table"}) passed away from unrelated causes.

The majority of *C. tropicalis* PJIs were treated with amphotericin B \[6; (60%), in 3 (50%) as monotherapy\], followed by fluconazole \[5; (50%), in 3 (60%) as monotherapy\], ketoconazole \[2; (20%), none as monotherapy\] and caspofungin \[1; (10%), not as monotherapy\]. Outcome was successful in 9 cases (90%; case number 66 in Table [1](#T1){ref-type="table"}, treated with fluconazole as monotherapy, did not provide information about outcome).

All patients suffering from *C. pelliculosa* PJI received fluconazole \[3 cases; (100%), 1 (33.3%) as monotherapy\], while 2 of them (66.7%) received amphotericin B (none as monotherapy). All patients (100%) were treated successfully. Both patients suffering from *C.lusitaniae* were treated successfully. Voriconazole was used as monotherapy in 1 case (50%), while amphotericin B and fluconazole were used in the other.

One patient suffering from *C. famata* was successfully treated with amphotericin B and fluconazole, while fluconazole as monotherapy was successfully used for the treatment of each case of *C. lipolytica* and *C. utilis* PJI. One case of *C. freyschussii* was successfully treated with fluconazole and caspofungin. A case of *C. guilliermondii* infection received amphotericin B, fluorocytosine and fluconazole, however, the result was failure. The mean antifungal treatment duration was 12.8 wk (SD = 10.9), while the mean follow-up of these cases was 33.3 mo (SD = 19.6).

DISCUSSION
==========

Fungal invasive infections, such as PJIs, due to *Candida* species have been acknowledged as a major cause of morbidity and mortality. These infections have been associated with progress in medical modalities, and is some cases have been considered iatrogenic\[[@B3],[@B4]\]. *Candida* PJIs are relative rare, since only case reports or small case series have been reported so far. *Candida albicans* is the most prevalent species. However, the incidence of invasive candidiasis and PJIs due to non-*albicans Candida* is increasing\[[@B5],[@B48]\]. Optimal treatment of these infections remains unclear, since no certain guidelines exist for the antifungal, as well as for the surgical treatments\[[@B48]\]. It is, therefore, of paramount importance to report such cases and to obtain a better understanding of treatment options and outcomes of these infections. The present study is an effort to review, in a systematic way, the non-*albicans Candida* PJI cases described in the literature. The study focuses on the preferred antifungal agent, the optimal surgical treatment, and the duration of therapy.

The electronic search has revealed a total of 83 patients with non-*albicans Candida* PJI. Their mean age was 66.3 years. Although *Candida* PJI is still considered rare, its incidence is expected to rise, due to the increasing number of joint arthroplasty surgeries performed worldwide\[[@B2],[@B48]\].

Several risk factors have been identified for invasive candidiasis, such as immunosuppression, long-term antimicrobial use and systemic disease\[[@B3],[@B4],[@B5],[@B48]\]. Such a patient profile has been illustrated by the relatively high mean Charlson comorbidity index of the present study's population, found to be 4.4.

*Candida* PJI is most commonly considered of hematogenous origin\[[@B2],[@B6],[@B48]\]. The mean time between initial arthroplasty surgery and symptomatology onset in the study population was 27.2 mo, while it ranged from immediately after surgery to 264 mo. It is of note that in 13 cases \[15.7%; cases 8, 23, 47, 51, 54, 55, 57, 60, 61, 69, 70, 82, 83 (Table [1](#T1){ref-type="table"})\] this time was found to be less than 1 mo. Therefore, in these cases the spread should be considered perioperative.

It is also of interest that the mean time between symptomatology onset and definite (culture-based) diagnosis was 7.5 mo, ranging from immediately after onset to 60 mo. This could be attributed to the fact that the main symptoms of *Candida* PJI are non-specific, which mainly include pain and swelling\[[@B1]-[@B5],[@B48]\]. The symptomatology onset may be mild, insidious and slowly progressive. Therefore, diagnosis may be delayed due to low suspicion index.

The most frequently isolated non-*albicans Candida* spp was *C. parapsilosis*, found in 45 cases (54.2%), followed by *C. glabrata* in 18 ( 21.7%), *C. tropicalis* in 10 (12%), *C pelliculosa* in 3 (3.6%), *C. lusitanae* in 2 ( 2.4%) and 1 case each (1.2%) of PJI caused by *C. famata*, *C. lipolytica*, *C. utitis*, *C. guillermondii* and *C. freyschussii*.

In the present study, *C. parapsilosis* was found to be the predominant pathogen causing PJIs, as compared to other non-*albicans Candida* species. *C. parapsilosis* prevalence has dramatically increased over the last 3 decades. Infections due to this pathogen are more frequently associated with prosthetic devices, indwelling catheters and hyperalimentation solutions. The pathogenesis of the infection depends on the expression of virulence factors, including adherence to host cells and tissues, biofilm formation and secretion of extracellular hydrolytic enzymes\[[@B5],[@B49]\].

The treatment of *C. parapsilosis* PJIs has proven to be successful in 88.9% of the studied cases. This is probably due to the fact that echinocandines were not used for the treatment of such cases, taking into account that *C. parapsilosis*' MICs are usually elevated to echinocandins, as compared to other *Candida* spp\[[@B50]\].

Treatment of *C. glabrata* PJIs has been successful in 94.4% of the studied cases. This is probably due to the fact that an azole compound has rarely been used for treatment and, in the limited number of cases when an azole was used, the drug has been given in combination with another antifungal, taking into account that *C. glabrata* is often resistant to azoles\[[@B50]\]. In most cases of *C. tropicalis* PJIs, treatment has been successful, since either single antifungal agents or combinations are known to be effective against this *Candida* spp.

All cases of *C. pelliculosa* PJIs have been treated successfully due to the use of effective agents. *C. lusitaniae* is intrinsically resistant to amphotericin B\[[@B50],[@B51]\]. One case received this agent in combination with fluconazole, while the other one was treated with voriconazole as monotherapy. Hence, finally, the 2 cases caused by *C. lusitanae* were successfully treated.

The cases of *C. famata*, *C. lypolitica* and *C. utilis* were successfully treated with the antifungals given. It is of note that the single case of *C. guillermondii*, although treated with a combination of antifungals, resulted in failure. For successful treatment, it is of the utmost importance to carry out susceptibility testing to obtain accurate MIC values following *Candida* isolation, taking into account that different *Candida* species are characterized by intrinsic resistance to certain antifungal compounds. Regarding the preferred antifungal agent, fluconazole was used in most cases \[59; (71%), in 31 of them (52.5%) as monotherapy\], followed by amphotericin B \[41; (49.4%), in 4 (9.8%) as monotherapy\]. Fluconazole has been rarely associated with severe hepatotoxicity. Therefore, liver function tests should be performed regularly during prolonged fluconazole therapy\[[@B50],[@B51]\]. Amphotericin B is an effective broad spectrum agent. However, it is relatively toxic and its side effects, including renal dysfunction, may restrict its long-term use, which is essential in PJI cases\[[@B6]\]. Echinocandines are the most recently developed anti-Candida agents. Although C. parapsilosis strains mostly exhibit high MICs, these agents can often be clinically effective due to their immunomodulatory properties and the fact that they successfully penetrate biofilms\[[@B52]\].

The mean duration of antifungal treatment in the study population was 12.8 wk, while it ranged from 1 to 53 wk. One case (case 32 in Table [1](#T1){ref-type="table"}) did not receive any antifungal treatment. Guidelines for the treatment of osteoarticular infections from *Candida* spp exist. However, no clear recommendations are available for the treatment of such PJIs\[[@B6],[@B48]\]. Therefore, the treatment duration is mainly based on the clinical and laboratory findings of each case.

Several options for surgical treatment have also been described. In the study population, in most cases (44 cases; 53%) a TSRA was performed, followed by RA (18 cases; 22%), OSRA (8 cases; 9.6%), arthrodesis (5 cases; 6%), debridement (3 cases; 3.6%) and amputation (2 cases; 2.4%).Three cases did not receive surgical treatment (3.6%; case 4, 55 and 82 in Table [1](#T1){ref-type="table"}). RA, arthrodesis, amputation and debridement are usually considered alternative options to arthroplasty exchange. TSRA had a statistically significant higher success rate when compared to OSRA (96% *vs* 73%; *P*-value = 0.023). Therefore, it seems more proper that TSRA should be considered as the optimal surgical intervention.

The present review has shown that non-*albicans Candida* PJIs represent a dangerous reality. Optimal management consists of a combination of the proper medical antifungal treatment based on susceptibility testing and surgical intervention. Although there have been reports of successful treatment of such cases with OSRA and debridement only, TSRA should be strongly recommended. The combination of TSRA separated by 3--6 mo and a prolonged period of antifungal therapy is suggested on the basis of limited data. Additional issues, such as the duration of antifungal therapy after prosthesis implantation (second stage of the TSRA), as well as the role of antifungal-loaded cement spacers, need to be addressed in order to determine the optimal treatment combinations.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Prosthetic joint infection (PJI) represents a severe complication of joint reconstruction surgery, causing total arthroplasty failure. Many pathogens have been identified in PJIs, such as Gram-positive and negative bacteria, while fungal microorganisms are considered rare causes, occurring in 1-2% of cases. *Candida* spp represent the most common fungal pathogens in these infections, with *Candida albicans* being the most prevalent species. However, the incidence of non-*albicans Candida* PJIs has increased over the last years. Hence, regarding non-*albicans Candida* PJIs, only case reports or small series have been reported so far. Optimal treatment is considered the two stage revision surgery in combination with an antifungal agent. However, no clear guidelines have yet been developed regarding the agent and treatment duration. Hence, a broad range of antifungal and surgical treatments has been reported so far. The present review article represents the first effort of evaluating the reported non-*albicans Candida* PJIs, aiming to clarify the treatment options of these infections and, possibly, to improve the medical and surgical care of such cases.

Research motivation
-------------------

The absence of clear guidelines regarding fungal PJIs represents a primary issue in managing these infections in clinical practice. A broad range of antifungal and surgical treatments have been reported, while treatment duration remains unclear. Furthermore, due to the limited data regarding these infections, information about patient demographics, responsible non- *albicans Candida* species, time between initial arthroplasty and symptom onset, time between symptom onset and definite diagnosis (culture), and outcome of the infection has not been reported in a systematic way. Hence, it is of utmost importance in the future to report such cases in order to obtain a better understanding about this devastating arthroplasty complication.

Research objectives
-------------------

The main objective of this study was to clarify, by systematically reviewing current published cases in the literature, the treatment options of non-*albicans Candida* PJIs and, possibly, to improve the medical and surgical care of such cases. During the process of reviewing the literature, it became apparent that information about patient demographics, fungal species, time between initial arthroplasty and symptom onset, time between symptom onset and definite diagnosis (culture), as well as outcome of the infection should also be reported, due to the absence of a systematic review regarding this topic.

Research methods
----------------

A meticulous electronic search of PubMed and MEDLINE databases was performed to identify all articles reporting the management of non-*albicans Candida* PJIs cases through April 2018 by two independent investigators. The citations in each article were reviewed to locate additional references that were not retrieved during the initial search. The evaluated parameters were patient demographics and comorbidities, affected joints, responsible non- *albicans Candida* species, duration and type of antifungal treatment, type of surgical treatment, time between initial arthroplasty and symptom onset, time between symptom onset and definite diagnosis (culture), and outcome of the infection. Data were recorded and analyzed using Microsoft Excel 2010 (Microsoft Corporation, Redmond, Washington). Two-sided Fisher's exact tests were used to compare success rates between groups. Statistical analyses were carried out at the 5% level of significance.

Research results
----------------

A total of 83 non-*albicans Candida* PJIs were located, with a mean age of 66.3 years (SD = 10.2). The knee was the affected joint in 52 cases (62.6%), the hip in 29 (35%) and the shoulder in 2 (2.4%). The mean time from arthroplasty to symptoms onset was found to be 27.2 mo (SD = 43), while the mean time from symptoms onset to culture-confirmed diagnosis was 7.5 mo (SD = 12.5). The most commonly isolated non-*albicans Candida* species was *C. parapsilosis*, found in 45 cases (54.2%), followed by *C. glabrata* in 18 (21.7%), *C. tropicalis* in 10 (12%), *C pelliculosa* in 3 (3.6%) and *C. lusitanae* in 2 (2.4%), while *C. famata*, *C. lipolytica*, *C. utilis*, *C. guilliermondii* and *C. freyschussii* had caused one case each (1.2%). A two stage revision arthroplasty (TSRA) was performed in most cases (44 cases; 53%), followed by RA (18 cases; 22%), OSRA (8 cases; 9.6%), arthrodesis (5 cases; 6%), debridement (3 cases; 3.6%) and amputation (2 cases; 2.4%), while 3 cases (3.6%) received no surgical treatment. TSRA when compared to OSRA had a higher success rate (96% *vs* 73%; *P*-value = 0.023). Fluconazole was used in most cases as antifungal treatment \[59; (71%), in 31 of them (52.5%) as monotherapy\], followed by amphotericin B \[41; (49.4%), in 4 (9.8%) as monotherapy\], flucytosine \[13; (15.7%), in 1 (7.7%) as monotherapy\], caspofungin \[7; (8.4%), in 1 (14.3%) as monotherapy\], voriconazole \[7; (8.4%), in 2 (28.6%) as monotherapy\], ketoconazole \[5; (6%), none as monotherapy\], itraconazole \[3; (3.6%), none as monotherapy\] and anidulafungin \[l; (1.2%), none as monotherapy\]. The final outcome was successful in 74 cases (89.2%). The mean antifungal treatment duration was 12.8 wk (SD = 10.9), while the mean follow-up of these cases was 33.3 mo (SD = 19.6). The present review has shown that the optimal management of non-*albicans Candida* consists of a combination of the proper medical antifungal treatment and surgical intervention. Although there have been reports of the successful treatment of such cases with OSRA and debridement only, TSRA should be strongly recommended. The combination of TSRA and a prolonged period of antifungal therapy based on susceptibility testing is suggested on the basis of limited data. Additional issues, such as the duration of antifungal therapy after prosthesis implantation (second stage of the TSRA) and the role of antifungal-loaded cement spacers need to be addressed in order to determine an optimal treatment combination.

Research conclusions
--------------------

The present study is an effort to review, in a systematic way, the non-*albicans Candida* PJI cases described in the literature. The study focuses on the preferred antifungal agent, the optimal surgical treatment, and the duration of therapy. *C. parapsilosis* was found to be the predominant pathogen causing PJIs, as compared to other non-*albicans Candida* species. For successful management of non-*albicans Candida* PJI, susceptibility testing to obtain accurate MIC values should always be performed following the *Candida* isolation, considering that different *Candida* species are characterized by intrinsic resistance to certain antifungal compounds. The mean duration of antifungal treatment in the present review was 12.8 wk, while it ranged from 1 to 53 wk. Although, guidelines for the treatment of osteoarticular infections from *Candida* spp are available, no clear recommendations exist for the treatment of such PJIs. Therefore, the treatment duration is mostly based upon clinical and laboratory findings. In most cases (44 cases; 53%) a TSRA was performed, followed by RA (18 cases; 22%), OSRA (8 cases; 9.6%), arthrodesis (5 cases; 6%), debridement (3 cases; 3.6%) and amputation (2 cases; 2.4%). Three cases did not receive surgical treatment (3.6%). RA, arthrodesis, amputation and debridement are usually considered alternative options to arthroplasty exchange. TSRA when compared to OSRA had a statistically significant higher success rate (96% *vs* 73%; *P*-value= 0.023). Therefore, it seems more proper that TSRA should be considered as the optimal surgical intervention. The present review has shown that the optimal management of non-*albicans Candida* PJIs consists of a combination of the proper medical antifungal treatment based on susceptibility testing and a surgical intervention, while TSRA should be strongly recommended. The combination of TSRA separated by 3--6 mo, in addition to a prolonged period of antifungal therapy, is suggested.

Research perspectives
---------------------

Non-*albicans Candida* PJIs represent a dangerous reality. The combination of TSRA separated by 3--6 mo and a prolonged period of antifungal therapy is suggested on the basis of limited data. It is of paramount importance to report the treatment of such cases, even the failed ones, in order to obtain a better understanding of these infections and to determine the optimum treatment combination.
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